EANS-News: AGENNIX AG / Agennix AG Announces Issuance of U.S. Patent Covering Use of Talactoferrin to Treat Non-Small Cell Lung Cancer and Renal Cell Carcinoma

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Patents, Copyright & Trademarks/Talactoferrin - Patent

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, March 23, 2011 - Agennix AG (Frankfurt Stock Exchange
(Prime Standard): AGX) today announced that the U.S. Patent and
Trademark Office has issued patent number 7,901,879, entitled,
"Lactoferrin in the treatment of malignant neoplasms and other
hyperproliferative diseases." The patent, which has a term until
2025, covers the use of oral human lactoferrins, including
talactoferrin, for the treatment of non-small cell lung cancer
(NSCLC) and renal cell carcinoma.

Torsten Hombeck, Ph.D., Chief Financial Officer and member of the
Company's Management Board, said: "This patent further strengthens
our intellectual property position for talactoferrin in a key market
and, importantly, covers the use of talactoferrin in its lead
indication, non-small cell lung cancer. We are pleased to have
recently completed enrollment in the FORTIS-M Phase III registration
trial evaluating talactoferrin for this use."

Agennix also reported that a patent application covering the use of
talactoferrin in lung cancer has recently received a Decision to
Grant in Japan. This patent would provide protection until 2023.
The Company has a patent application pending in Europe related to the
use of talactoferrin in oncology.

About talactoferrin Talactoferrin is an oral biologic therapy with
immunomodulatory and antibacterial properties, which is being studied
for the treatment of cancer and severe sepsis. Talactoferrin has
demonstrated promising activity in randomized, double-blind,
placebo-controlled Phase II studies in NSCLC, as well as in severe
sepsis. Two Phase III trials with talactoferrin in NSCLC are ongoing,
and one - the FORTIS-M trial -completed enrollment in March 2011.
NSCLC is one of the most common types of cancer worldwide and the
most frequent cause of cancer death. Agennix also plans to develop
talactoferrin further for the treatment of severe sepsis and plans to
initiate a Phase II/III trial in that indication. Talactoferrin has
been shown to be very well tolerated in these patient populations.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing, and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix's registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. There can be no guarantee
that talactoferrin will be approved for marketing for non-small cell
lung cancer or any other indication in a timely manner, if at all.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

Agennix(TM) is a trademark of the Agennix group.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade